Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ZF 2001

Next Previous
X
Search
Drug Profile

ZF 2001

Alternative Names: Coronavirus vaccine - Anhui Zhifei Longcom Biopharmaceutical/Institute of Microbiology of the Chinese Academy of Sciences; COVID-2019 vaccine - Anhui Zhifei Longcom Biologic Pharmaceutical/Institute of Microbiology of the Chinese Academy of Sciences; Recombinant new coronavirus vaccine (CHO cell) - Anhui Zhifei Longcom Biopharmaceutical/Institute of Microbiology of the Chinese Academy of Sciences; Recombinant novel coronavirus vaccine (CHO Cell) - Anhui Zhifei Longcom Biopharmaceutical/Institute of Microbiology of the Chinese Academy of Sciences; ZF-2001; ZF-UZ-VAC 2001; ZIFIVAX

Latest Information Update: 21 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Anhui Zhifei Longcom Biopharmaceutical; Institute of Microbiology of the Chinese Academy of Sciences
  • Developer Anhui Zhifei Longcom Biopharmaceutical
  • Class COVID-19 vaccines; Synthetic vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered COVID 2019 infections

Most Recent Events

  • 20 May 2024 Anhui Zhifei Longcom Biologic Pharmacy completes a clinical trial for COVID-2019 infections (Prevention) in China (IM, injection) (NCT05850507)
  • 25 Sep 2023 Anhui Zhifei Longcom Biopharmaceutical plans a phase I trial for COVID-2019 infections (Prevention) (IM, Injection) in September 2023 (NCT06043388)
  • 06 Sep 2023 Anhui Zhifei Longcom Biopharmaceutical plans a phase II trial for COVID-2019 infections (Prevention) in China (IM) in September 2023 (NCT06025812)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top